BV‐CHP is clearly the standard of care option for ALCL that show strong expression for CD30 whilst the benefit of this regimen in PTCL‐NOS and AITL subgroups that express CD30 not uniformly is uncertain. This evidence concerns the gene TNFRSF8 and angioimmunoblastic T-cell lymphoma.